Earnings Call Summary | Nanobiotix(NBTX.US) Q1 2024 Earnings Conference
Earnings Call Summary | Nanobiotix(NBTX.US) Q1 2024 Earnings Conference
They're working on two more platforms, Curadigm and Oocuity, focusing on nanoparticle-based therapies.The following is a summary of the Nanobiotix S.A. (NBTX) Q1 2024 Earnings Call Transcript:
以下是Nanobiotix S.A.（NBTX）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Nanobiotix reported a Q1 2024 unaudited cash balance of €58.9 million and reassured its cash availability until Q3 2025, including the recently received $20 million milestone.
Nanobiotix報告稱，2024年第一季度未經審計的現金餘額爲5,890萬歐元，並保證其在2025年第三季度之前的現金可用性，包括最近獲得的2000萬美元里程碑。
Business Progress:
業務進展：
Nanobiotix is progressing with NBTXR3, joining forces with Janssen for global commercialization.
They're working on two more platforms, Curadigm and Oocuity, focusing on nanoparticle-based therapies.
Their ongoing collaboration with the MD Anderson Cancer Center plans to have multiple study readouts in the next 12 months.
The company is shifting the sponsorship of the NANORAY-312 trial to Janssen in preparation for potential regulatory submission.
Upon securing more funding, Nanobiotix plans to initiate a new Phase 2 study in a new indication after the NANORAY-312 sponsorship transfer.
They look forward to completing patient recruitment by H1 '26, potential additions to funding and publishes regular updates scheduled for H2 '24.
A crucial update on FDA's approval on the randomized Phase 2 lung cancer trial design is soon to be published. Data on NBTXR3 will also be presented at ASCO.
Nanobiotix 正在 NBTXR3 方面取得進展，與詹森聯手實現全球商業化。
他們正在開發另外兩個平台，即Curadigm和Ocuity，專注於基於納米顆粒的療法。
他們與MD安德森癌症中心的持續合作計劃在未來12個月內發佈多份研究報告。
該公司正在將 NANORAY-312 試驗的贊助權轉移給詹森，爲監管部門可能提交的文件做準備。
在獲得更多資金後，Nanobiotix計劃在 NANORAY-312 贊助轉讓後啓動一項針對新適應症的新2期研究。
他們期待在26年上半年完成患者招募，可能增加資金，並定期發佈計劃於24年下半年發佈最新消息。
美國食品藥品管理局批准隨機2期肺癌試驗設計的重要更新即將公佈。NBTXR3 的數據也將在 ASCO 上公佈。
More details: Nanobiotix IR
更多詳情： Nanobiotix 紅外線
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。